Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2001-10-09
2008-12-16
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100, C424S141100, C530S388100
Reexamination Certificate
active
07465790
ABSTRACT:
A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
REFERENCES:
patent: 6069301 (2000-05-01), Carozzi et al.
patent: WO 97/31024 (1997-08-01), None
Gilliland et al (The Journal of Immunology 162:3663-3671, 1999).
Hale (immunology 1:175-187, 1995.
Hale G., Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology. Dec. 1995;1(3-4):175-87.
W. Burgess, AShaheen, et al., Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,The Journal of Cell Biology. Vo. 111, 1990, 2129-2138.
Mathews and Van Holde, Biochemistry, 1996, pp. 165-171.
M. Wing et al., T. Moreau Mechanism of first-dose cytokien-release syndrome by CAMPATH 1-H: involvement of CD16 (Fc RIII) and CD11a/CD18(LFA-1) on NK cells. J CLin Invest vol. 98, p. 2819-26, 1996.
Abbas et al., cellular and molecular immunology, p. 59, 4th edition by W.B. Saunders company, 2000.
Gilliland et al., J of Immunology, vol. 162, p. 3663-3671, 1999.
Leader et al., Immunology, vol. 72, p. 481-485, 1991.
Rudikoff et al., Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979.
Hale,Immunotechnology, vol. 1, pp. 175-187 (1995).
Gilliland, et al.,J. Immunol., vol. 162, pp. 3663-3671 (1999).
Frewin Mark Raymond
Gilliland Lisa Kim
Simoes da Silva Graca Luis Richardo
Waldmann Herman
Helms Larry R.
ISIS INNOVATION, Inc.
Lillie Raymond J.
Olstein Elliot M.
Yao Lei
LandOfFree
Therapeutic antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4027211